RADICALS trial in prostate cancer – part 8
Posted by admin on Sep 11, 2009 under Prostate Cancer Clinical Trials
When is the best time to approach men about RADICALS?
Chris Parker
Chief Investigator
Duration : 0:0:39
RADICALS trial in prostate cancer – part 7
Posted by admin on Sep 9, 2009 under Prostate Cancer Clinical Trials
What is the main outcome measure in the RADICALS trial?
Chris Parker
Chief Investigator
Duration : 0:0:45
RADICALS trial in prostate cancer – part 6
Posted by admin on Sep 7, 2009 under Prostate Cancer Clinical Trials
Which groups of men could join the RADICALS trial?
Chris Parker
Chief Investigator
Duration : 0:1:6
Advances in Radiation Therapy for Cancer Treatment
Posted by admin on Sep 5, 2009 under Prostate Cancer Clinical Trials
Learn more at http://www.mdanderson.org/care_centers/radiationonco/
Radiation therapy in cancer treatment has advanced significantly in the past few years because of clinical trials and breakthroughs in technology and computer imaging, and use of proton therapy. M D Anderson is working toward improving use, and lessing side effects of radiation treatment.
Duration : 0:2:45
RADICALS trial in prostate cancer – part 5
Posted by admin on Sep 1, 2009 under Prostate Cancer Clinical Trials
What is the role of hormone therapy with post-operative radiotherapy?
Chris Parker
Chief Investigator
Duration : 0:0:42
New Prostate Cancer Procedure Being Tested in US Clinical Tr
Posted by admin on Aug 29, 2009 under Prostate Cancer Clinical Trials
New Prostate Cancer Procedure Being Tested in US Clinical Trials International HIFU
High Intensity Focused Ultrasound (HIFU) Procedure Reduces Side Effects, May Increase Quality of Life
January 2009 According to the American Cancer ociation, prostate cancer affects one in six men in the U.S. and is the second leading cause of cancer deaths in men. When caught and treated early, survival rates can be more than 90 percent, making swift treatment key.
Existing treatments however, can be limited and affect quality of life due to significant side effects, including loss of muscle mass, depression, decreased mental acuity and impotence. Now a High Intensity Focused Ultrasound (HIFU) procedure, available in 33 countries outside the US including Europe, is being tested in US Phase III clinical trials. HIFU is a minimally invasive procedure that uses the Sonablate(r) 500 ultrasound device to destroy cancerous tissue with focused sound waves.
By focusing sound waves in a targeted area, HIFU can rapidly increase the temperature in the focal zone, causing tissue destruction. This procedure is radiation-free and doesn’t preclude any other treatment options.
For more and more information regarding the risks and benefits ociated with HIFU, go to www.InternationalHIFU.com.
NOTE: Sonablate(r) 500 is not approved for use in the U.S. It remains investigational in the U.S. and is being studied as a prostate cancer treatment in clinical trials in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate(r)500 for the treatment of prostate cancer. USHIFU is a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies. International HIFU is the entity through which USHIFU conducts its international business operations and makes the HIFU technologies available to US patients at centers outside the United States where such technologies are approved.
Duration : 0:0:56
New Prostate Cancer Procedure Being Tested in US Clinical Tr
Posted by admin on Aug 27, 2009 under Prostate Cancer Clinical Trials
New Prostate Cancer Procedure Being Tested in US Clinical Trials International HIFU
High Intensity Focused Ultrasound (HIFU) Procedure Reduces Side Effects, May Increase Quality of Life
January 2009 According to the American Cancer ociation, prostate cancer affects one in six men in the U.S. and is the second leading cause of cancer deaths in men. When caught and treated early, survival rates can be more than 90 percent, making swift treatment key.
Existing treatments however, can be limited and affect quality of life due to significant side effects, including loss of muscle mass, depression, decreased mental acuity and impotence. Now a High Intensity Focused Ultrasound (HIFU) procedure, available in 33 countries outside the US including Europe, is being tested in US Phase III clinical trials. HIFU is a minimally invasive procedure that uses the Sonablate(r) 500 ultrasound device to destroy cancerous tissue with focused sound waves.
By focusing sound waves in a targeted area, HIFU can rapidly increase the temperature in the focal zone, causing tissue destruction. This procedure is radiation-free and doesn’t preclude any other treatment options.
For more and more information regarding the risks and benefits ociated with HIFU, go to www.InternationalHIFU.com.
NOTE: Sonablate(r) 500 is not approved for use in the U.S. It remains investigational in the U.S. and is being studied as a prostate cancer treatment in clinical trials in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate(r)500 for the treatment of prostate cancer. USHIFU is a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies. International HIFU is the entity through which USHIFU conducts its international business operations and makes the HIFU technologies available to US patients at centers outside the United States where such technologies are approved.
Duration : 0:3:37
RADICALS trial in prostate cancer – part 1
Posted by admin on Aug 25, 2009 under Prostate Cancer Clinical Trials
What is the current standard of care for men with prostate cancer after radical prostatectomy?
Chris Parker, Chief Investigator
Duration : 0:0:55
Design of the RADICALS trial in prostate cancer
Posted by admin on Aug 23, 2009 under Prostate Cancer Clinical Trials
Summary of the trial design for the RADICALS trial for men with prostate cancer
Matt Sydes
Trial Statistician
Duration : 0:8:7
New Prostate Cancer Procedure Being Tested in US Clinical Tr
Posted by admin on Aug 21, 2009 under Prostate Cancer Clinical Trials
New Prostate Cancer Procedure Being Tested in US Clinical Trials International HIFU
High Intensity Focused Ultrasound (HIFU) Procedure Reduces Side Effects, May Increase Quality of Life
January 2009 According to the American Cancer ociation, prostate cancer affects one in six men in the U.S. and is the second leading cause of cancer deaths in men. When caught and treated early, survival rates can be more than 90 percent, making swift treatment key.
Existing treatments however, can be limited and affect quality of life due to significant side effects, including loss of muscle mass, depression, decreased mental acuity and impotence. Now a High Intensity Focused Ultrasound (HIFU) procedure, available in 33 countries outside the US including Europe, is being tested in US Phase III clinical trials. HIFU is a minimally invasive procedure that uses the Sonablate(r) 500 ultrasound device to destroy cancerous tissue with focused sound waves.
By focusing sound waves in a targeted area, HIFU can rapidly increase the temperature in the focal zone, causing tissue destruction. This procedure is radiation-free and doesn’t preclude any other treatment options.
For more and more information regarding the risks and benefits ociated with HIFU, go to www.InternationalHIFU.com.
NOTE: Sonablate(r) 500 is not approved for use in the U.S. It remains investigational in the U.S. and is being studied as a prostate cancer treatment in clinical trials in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate(r)500 for the treatment of prostate cancer. USHIFU is a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies. International HIFU is the entity through which USHIFU conducts its international business operations and makes the HIFU technologies available to US patients at centers outside the United States where such technologies are approved.
Duration : 0:2:49